Selenium in combination with a tomato lipid extract as a therapy for benign prostatic hyperplasia and its alterations in rats with induced BPH
Journal of Cellular and Molecular Medicine · 2023
DOI: 10.1111/jcmm.17903 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2023. Verfasst von David Julian Arias-Chávez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Departmento de Farmacobiología, Centro de Investigación y de Estudios Avanzados del IPN, Sede Sur, Mexico City, Mexico. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, Solanum lycopersicum, Selenium, Plant Extracts. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Consejo Nacional de Ciencia y Tecnología.
Abstract (Originalsprache)
Benign prostatic hyperplasia (BPH) is the most common adenoma in old men. Tomatoes are a rich source of bioactive compounds that, as well as selenium (Se), possess antioxidant and antiproliferative activity. The aim was to evaluate the therapeutic effect of Se in combination with a tomato extract in aged rats with BPH. Aged male Wistar rats were divided in the following groups ( n = 10 rats/group): Control (C), BPH, BPH + Finasteride (BPH + F), BPH + Tomato Lipidic Extract (BPH + E), BPH + Selenium (BPH + S) and BPH plus E plus S (BPH + E + S). After 4 weeks of treatment, prostate weight, diuresis, antioxidants enzymes, prooxidants and inflammatory markers, growth factors and androgens were determined. BPH + E + S reduced prostate weight by 59.29% and inhibited growth by 99.35% compared to BPH + F which only decreased weight and inhibited growth by 15.31% and 57.54%, respectively. Prooxidant markers were higher with BPH + F (49.4% higher vs. BPH), but BPH + E + S decreased these markers (94.27% vs. BPH) and increased antioxidant activity. Finally, diuresis was higher with the BPH + E + S combination and markers of inflammation and growth factors were significantly lower with respect to BPH + F. Our findings provide a beneficial and protective therapeutic option of E + S directed against androgens, oxidative stress and inflammation that regulates cell proliferation in the prostate gland.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departmento de Farmacobiología, Centro de Investigación y de Estudios Avanzados del IPN, Sede Sur, Mexico City, Mexico.
- Departamento de Patología, ISSSTE, Hospital General Dra. Matilde Petra Montoya Lafragua, Mexico City, Mexico.
- Departamento de Patología, Hospital Ángeles Lindavista, Mexico City, Mexico.
- Laboratorio F-315, Departamento de Biología, Facultad de Química, Universidad Nacional Autónoma de México, Mexico City, Mexico.
ORCID-Profile: David Julian Arias-Chávez
Förderung
- Consejo Nacional de Ciencia y Tecnología
Zitieren
APA
Arias-Chávez, D. J., Mailloux-Salinas, P., Ledesma Aparicio, J., Campos-Pérez, E., Medina-Campos, O. N., Pedraza-Chaverri, J., & Bravo, G. (2023). Selenium in combination with a tomato lipid extract as a therapy for benign prostatic hyperplasia and its alterations in rats with induced BPH. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.17903
Vancouver
Arias-Chávez DJ, Mailloux-Salinas P, Ledesma Aparicio J, Campos-Pérez E, Medina-Campos ON, Pedraza-Chaverri J, et al. Selenium in combination with a tomato lipid extract as a therapy for benign prostatic hyperplasia and its alterations in rats with induced BPH. Journal of Cellular and Molecular Medicine. 2023. doi:10.1111/jcmm.17903
BibTeX
@article{AriasChvez2023,
author = {Arias-Chávez, David Julian and Mailloux-Salinas, Patrick and Ledesma Aparicio, Jessica and Campos-Pérez, Elihu and Medina-Campos, Omar Noel and Pedraza-Chaverri, José and Bravo, Guadalupe},
title = {Selenium in combination with a tomato lipid extract as a therapy for benign prostatic hyperplasia and its alterations in rats with induced BPH},
journal = {Journal of Cellular and Molecular Medicine},
year = {2023},
doi = {10.1111/jcmm.17903}
}
EUVIMED